To explore the effect of multi-mode neuroanalgesic adjuvant on stress response and immune function in laparoscopic radical resection of colon cancer by posterior transverse abdominal fascia block

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065816

Enrollment

Unknown

Registered

2022-11-16

Start date

2022-12-15

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon cancer

Interventions

control group:Bilateral posterior TAP block was performed with 20mL of 0.2% ropivacaine on each side

Dexmedetomidine group:20mL of 0.2% ropivacaine + 25ug dexamete on each side bilateral posterior TAP block of Tomidine

Dexamethasone group:Bilateral posterior TAP block with 0.2% ropivacaine + 4mg dexamethasone at 20mL on each side

Dexmedetomidine combined with dexamethasone group:Bilateral posterior TAP block was performed with 20mL of 0.2% ropivacaine + 25ug dexmedetomidine + 4mg dexamethasone on each side

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective laparoscopic radical resection of colon cancer; 2. Aged 18-75 years, no gender limitation; 3. ASA grade I-II; 4. Colonoscopy or operative and postoperative pathological diagnosis of colon cancer; 5. No damage or infection of abdominal skin.

Exclusion criteria

Exclusion criteria: 1. High blood pressure; 2. Allergy to study drugs and refusal to participate in the study; 3. Women who are pregnant or breastfeeding; 4. Preoperative heart rate less than 50 beats/min, heart rhythm disorder; 5. Serious heart, liver, kidney and endocrine diseases; 6. Diseases of blood system or immunity; 7. Mental illness; 8. Diabetes; 9. Preoperative examination suggested distant metastasis; 10. Long-term treatment with adrenergic agonists or antagonists; 11. Chronic pain treatment or long-term use of steroids; 12. Body mass index > 40; 13. Sleep apnea syndrome.

Design outcomes

Primary

Measure	Time frame
Duration of analgesic effect of TAP;Consumption of sufentanil ;visual analogue scale;Sedation scores;Comfort score;blood glucose;serum cortisol;adrenaline;norepinephrine;c-reactive protein;Number of CD4 + TT cells;Number of CD8 + TT cells;Ratio of CD4 + TT cells to CD8 + TT cells;NK cell number;Serum interferon ? (IFN-?) levels;	—

Secondary

Measure	Time frame
Postoperative bowel sounds recovery time;Time of first anal exhaust;Time to start your first liquid diet;D - lactic acid;Small intestine type fatty acid binding protein (I-FABP);Early ambulation time;length of stay;	—

Countries

China

Contacts

Public ContactSu Changsheng

Quanzhou First Hospital affiliated to Fujian Medical University

981835422@qq.com+86 15880435824

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026